BVXV:NSD-BiondVax Pharmaceuticals Ltd (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.32

Change

+0.01 (+0.76)%

Market Cap

USD 0.02B

Volume

0.03M

Avg Analyst Target

USD 7.00 (+430.30%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

BiondVax Pharmaceuticals Ltd (BVXV) Stock Analysis:
Based on the BiondVax Pharmaceuticals Ltd stock forecasts from 1 analysts, the average analyst target price for BiondVax Pharmaceuticals Ltd is USD 7.00 over the next 12 months. BiondVax Pharmaceuticals Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BiondVax Pharmaceuticals Ltd is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, BiondVax Pharmaceuticals Ltd’s stock price was USD 1.32. BiondVax Pharmaceuticals Ltd’s stock price has changed by +2.33% over the past week, -16.98% over the past month and -53.36% over the last year.

About

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agre ...Read More

Company Website : https://www.biondvax.com

Address : Jerusalem BioPark Building, Jerusalem, Israel

Employees : 15

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 2.52

52 Week High : 4.19

Short Ratio : 0.38

52 Week Low : 1.00

Shorted Shares : 73,722

200 Day Moving Average : 1.88

Shorted Shares Previous Month : 124,342

50 Day Moving Average : 1.45

Shares Held By Insiders : 22.95%

Short Percentage : 4.72%

Shares Held by Institutions : 1.83%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+9.49 (+1.47%)

 USD70.91B 8.97 6.88
VRTX Vertex Pharmaceuticals Incorpo..

+7.45 (+3.02%)

 USD63.10B 27.38 17.74
MRNA Moderna Inc

-1.65 (-1.20%)

 USD54.86B 4.87 2.41
ALXN Alexion Pharmaceuticals Inc

N/A

 USD40.34B 59.23 42.56
BNTX BioNTech SE

-7.64 (-4.81%)

 USD38.60B 3.81 1.75
RPRX Royalty Pharma plc

+0.32 (+0.80%)

 USD26.93B 26.81 14.86
SGEN Seagen Inc

+6.91 (+5.09%)

 USD24.97B 55.02 44.86
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A
GMAB Genmab A/S

+0.06 (+0.20%)

 USD19.19B 46.16 5.06
ARGX argenx SE

-2.74 (-0.88%)

 USD16.75B N/A N/A

ETFs Containing BVXV

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -43.83% 56% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -43.83% 56% F 28% F
Trailing 12 Months  
Capital Gain -53.68% 61% D- 29% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -53.68% 61% D- 29% F
Trailing 5 Years  
Capital Gain -82.97% 32% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -82.97% 32% F 9% F
Average Annual (5 Year Horizon)  
Capital Gain 30.45% 73% C 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.45% 73% C 81% B-
Risk Return Profile  
Volatility (Standard Deviation) 168.64% 13% F 7% F
Risk Adjusted Return 18.05% 58% F 47% F
Market Capitalization 0.02B 14% F 10% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.32 23% F 24% F
Price / Cash Flow Ratio -1.00 26% F 56% F
EV/EBITDA 2.83 25% F 77% C+
Management Effectiveness  
Return on Equity -915.14% 3% F 2% F
Return on Invested Capital -52.61% 52% F 19% F
Return on Assets -27.82% 44% F 14% F
Debt to Equity Ratio 271.08% 7% F 8% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.38 92% A- 87% B+
Short Percent 4.72% 51% F 36% F
Beta 2.52 6% F 5% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector